Identifying and Targeting Hypoxia in Head and Neck Cancer: A Brief Overview of Current Approaches

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2 SUPPL., 2007, Pages

  Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; BENZAMIDE DERIVATIVE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOGEN; CARBONATE DEHYDRATASE IX; CISPLATIN; EPHRIN A1; ERYTHROPOIETIN; FLUOROURACIL; GALECTIN 1; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1; MUSTARD GAS DERIVATIVE; NICOTINAMIDE; OSTEOPONTIN; OXYGEN; PIMONIDAZOLE; PR 104; PROTEIN LYSINE 6 OXIDASE; TIRAPAZAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; DISEASE MARKER; DRUG POTENCY; DRUG TARGETING; ELECTRODE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; HYPOXIC CELL; LARYNX CANCER; OROPHARYNX CANCER; OXYGEN TENSION; OXYGENATION; PHOTON EMISSION TOMOGRAPHY; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; ELECTRODES; ETANIDAZOLE; HEAD AND NECK NEOPLASMS; HUMANS; HYDROCARBONS, FLUORINATED; NEOPLASM PROTEINS; NITROIMIDAZOLES; OSTEOPONTIN; OXYGEN; PARTIAL PRESSURE; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 34548446807     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.081     Document Type: Article

References (17)

1. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77 (2005) 18-24
2. Wendling P., Manz R., Thews G., et al. Heterogeneous oxygenation of rectal carcinomas in humans: A critical parameter for preoperative irradiation?. Adv Exp Med Biol 180 (1984) 293-300
3. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58 (1998) 3765-3768
4. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60 (2000) 2018-2024
5. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
6. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
7. Riedel F., Gotte K., Schwalb J., et al. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257 (2000) 332-336
8. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9 (2003) 59-67
9. Bache M., Reddemann R., Said H.M., et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 66 (2006) 1481-1485
10. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
11. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
12. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
13. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
14. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
15. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
16. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
17. Le Q.T., Taira A., Budenz S., et al. Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106 (2006) 1940-1949